<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="dexamethasone, interferons, statins, angiotensin pathway modulators, macrolides (e.g. azithromycin, clarithromycin)," exact="hydroxychloroquine" post="and chloroquine, colchicine, and prostaglandin D2 modulators such as"/>
 <result pre="as endorsement for use of such agents. The use of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 patients may be associated with"/>
 <result pre="for use of such agents. The use of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 patients may be associated with harm. Whether"/>
 <result pre="who received tocilizumab (80â€&quot;600Â mg per dose) in combination with" exact="methylprednisolone" post="in 8 of the patients. Five patients received two"/>
 <result pre="the management of CRS in severely ill COVID-19 patients [32]." exact="Ruxolitinib" post="(JakafiÂ®) is a potent and selective oral inhibitor of"/>
 <result pre="high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease [33]." exact="Ruxolitinib" post="interrupts signaling downstream of multiple proinflammatory cytokines, which constitute"/>
 <result pre="againstÂ viruses [34]. In addition, severe reactions afterÂ initiationÂ ofÂ" exact="ruxolitinib" post="were reported in two COVID-19 patients, and required drug"/>
 <result pre="of ritonavir, a CYP3A4 inhibitor, leading to an increase in" exact="ruxolitinib" post="plasma concentrations. Thus, the role and safety of this"/>
 <result pre="currently no published clinical trials to support the use of" exact="ruxolitinib" post="or other JAK inhibitors in COVID-19. Two ongoing phase"/>
 <result pre="randomized clinical trials are evaluating the efficacy and safety of" exact="ruxolitinib" post="plus standard of care, compared with standard-of-care therapy alone,"/>
 <result pre="high-titer neutralizing antibodies (NAT of 80â€&quot;480) in conjunction with continued" exact="methylprednisolone" post="and antiviral treatment [73]. Before transfusion, patients displayed continuously"/>
 <result pre="with ARDS, providing that a low dose (â‰¤â€‰0.5â€&quot;1Â mg/kg/day of" exact="methylprednisolone" post="or equivalent) and short duration (â‰¤â€‰7Â days) are used"/>
 <result pre="on preliminary results from the RECOVERY trial, which showed that" exact="dexamethasone" post="reduces mortality among COVID-19 patients with severe respiratory complications"/>
 <result pre="mortality among COVID-19 patients with severe respiratory complications [97]. Low-dose" exact="dexamethasone" post="(6Â mg once daily, orally or intravenously) for 10Â"/>
 <result pre="multicenter, randomized controlled trial (DEXA-ARDS) studied the effects of intravenous" exact="dexamethasone" post="at a dose of 20Â mg once daily on"/>
 <result pre="[98]. Compared with those receiving conventional treatment, the addition of" exact="dexamethasone" post="to the therapy regimen lead to a reduction in"/>
 <result pre="with confirmed COVID-19 infection has commenced (NCT04325061). Compared with methylprednisolone," exact="dexamethasone" post="has less mineralocorticoid activity and is less likely to"/>
 <result pre="a concern in this patient population [90]. The use of" exact="methylprednisolone" post="in severe COVID-19 patients was evaluated in several retrospective,"/>
 <result pre="pneumonia that progressed to acute respiratory failure, the use of" exact="methylprednisolone" post="1â€&quot;2Â mg/kg daily intravenously for 5â€&quot;7Â days in 26"/>
 <result pre="whom received methylprednisolone. Wu et al. showed that treatment with" exact="methylprednisolone" post="decreased the risk of death (HR 0.38, 95% CI"/>
 <result pre="0.20â€&quot;0.72, pâ€‰=â€‰0.003) among patients with ARDS [6]. Higher doses of" exact="methylprednisolone" post="have been recommended for managing the cytokine storm: methylprednisolone"/>
 <result pre="of methylprednisolone have been recommended for managing the cytokine storm:" exact="methylprednisolone" post="60â€&quot;125Â mg every 6Â h for up to 3Â"/>
 <result pre="retrospective cohort study of 44 patients investigated the use of" exact="ribavirin" post="and INFÎ±-2a compared with ribavirin alone for the management"/>
 <result pre="patients investigated the use of ribavirin and INFÎ±-2a compared with" exact="ribavirin" post="alone for the management of severe MERS. The study"/>
 <result pre="therapy should be started or continued. Macrolides Macrolides, such as" exact="azithromycin" post="and clarithromycin, are antibiotics with immunomodulatory and anti-inflammatory effects"/>
 <result pre="the exact mechanisms of these effects are not fully illuminated." exact="Azithromycin" post="has been used as an adjunctive therapy to provide"/>
 <result pre="al., patients with moderate or severe ARDS who received adjunctive" exact="azithromycin" post="manifested a significant improvement in 90-day survival [129]. In"/>
 <result pre="to draw any firm conclusions about the benefits of adjunctive" exact="azithromycin" post="in COVID-19 patients. Furthermore, this antibiotic is known to"/>
 <result pre="outpatients receiving this therapy in combination with other QT-prolonging therapies." exact="Hydroxychloroquine" post="and Chloroquine It has been postulated that hydroxychloroquine and"/>
 <result pre="this therapy in combination with other QT-prolonging therapies. Hydroxychloroquine and" exact="Chloroquine" post="It has been postulated that hydroxychloroquine and chloroquine exhibit"/>
 <result pre="QT-prolonging therapies. Hydroxychloroquine and Chloroquine It has been postulated that" exact="hydroxychloroquine" post="and chloroquine exhibit immunomodulatory effects that theoretically may confer"/>
 <result pre="Hydroxychloroquine and Chloroquine It has been postulated that hydroxychloroquine and" exact="chloroquine" post="exhibit immunomodulatory effects that theoretically may confer an anti-inflammatory"/>
 <result pre="open-label, randomized trial indicated the potentially beneficial anti-inflammatory effect of" exact="hydroxychloroquine" post="in patients with COVID-19 [143]. While adding hydroxychloroquine to"/>
 <result pre="effect of hydroxychloroquine in patients with COVID-19 [143]. While adding" exact="hydroxychloroquine" post="to the standard of care did not increase virus"/>
 <result pre="from hydroxychloroquine. If these findings are confirmed in larger studies," exact="hydroxychloroquine" post="may be indicated to decrease the risk of progressive"/>
 <result pre="agent also prolongs the QT interval, and the combination of" exact="hydroxychloroquine" post="and azithromycin could produce additive and potentially dangerous QT"/>
 <result pre="prolongs the QT interval, and the combination of hydroxychloroquine and" exact="azithromycin" post="could produce additive and potentially dangerous QT prolongation [144]."/>
 <result pre="data of 1376 patients who received hydroxychloroquine, 811 (58.9%) received" exact="hydroxychloroquine" post="and 565 (41.1%) did not. The primary endpoint was"/>
 <result pre="346 patients (25.1%), and there was no significant association between" exact="hydroxychloroquine" post="use and the composite primary endpoint (HR 1.04, 95%"/>
 <result pre="trial by Boulware et al. [146] evaluated the use of" exact="hydroxychloroquine" post="as a potential agent for post-exposure prophylaxis in 821"/>
 <result pre="was to identify new COVID-19 infections between patients who received" exact="hydroxychloroquine" post="or placebo. Within 4Â days of exposure, patients were"/>
 <result pre="exposure, patients were randomized to either a 5-day regimen of" exact="hydroxychloroquine" post="or placebo. While there were slightly fewer infections in"/>
 <result pre="or placebo. While there were slightly fewer infections in the" exact="hydroxychloroquine" post="arm (11.8% vs. 14.3%), the difference was not statistically"/>
 <result pre="15 June 2020. The basis of this decision is that" exact="hydroxychloroquine" post="or chloroquine are unlikely to be effective in treating"/>
 <result pre="2020. The basis of this decision is that hydroxychloroquine or" exact="chloroquine" post="are unlikely to be effective in treating COVID-19, above"/>
 <result pre="consistently replicated. Preliminary results from the RECOVERY trial reported that" exact="hydroxychloroquine" post="did not provide a significant difference in the primary"/>
 <result pre="difference in the primary endpoint of 28-day mortalityâ€&quot;25.7% in the" exact="hydroxychloroquine" post="arm and 23.5% in the usual-care arm (HR 1.11,"/>
 <result pre="the ORCHID study, which evaluated the safety and effectiveness of" exact="hydroxychloroquine" post="for the treatment of COVID-19 in hospitalized adults, was"/>
 <result pre="et al. evaluated the efficacy and safety of two different" exact="chloroquine" post="dosages as adjunctive therapy in hospitalized patients with severe"/>
 <result pre="The 81 enrolled patients were randomized to receive either high-dose" exact="chloroquine" post="(i.e. 600Â mg twice daily for 10Â days) or"/>
 <result pre="(i.e. 600Â mg twice daily for 10Â days) or low-dose" exact="chloroquine" post="(i.e. 450Â mg twice daily on day 1 and"/>
 <result pre="the treatment of severe COVID-19, particularly in patients also receiving" exact="azithromycin" post="and oseltamivir. The study continues to evaluate the low-dose"/>
 <result pre="of CYP3A4 substrates Safety during pregnancy and lactation is unknown" exact="Ruxolitinib" post="Various regimens under investigation 5Â mg bid for 14Â"/>
 <result pre="increased macrophage-dependent infection, tuberculosis, opportunistic infections, injection site reactions, increased" exact="creatine" post="phosphokinase, headache, rash None Avoid use with anakinra due"/>
 <result pre="with the smallest possible effective dose for the shortest duration" exact="Methylprednisolone" post="0.5â€&quot;1Â mg/kg daily or 1â€&quot;2Â mg/kg daily (of methylprednisolone"/>
 <result pre="duration Methylprednisolone 0.5â€&quot;1Â mg/kg daily or 1â€&quot;2Â mg/kg daily (of" exact="methylprednisolone" post="or equivalent) have been proposed Higher doses (cytokine storm):"/>
 <result pre="patients with pre-existing heart disease and organ transplant Miscellaneous Statins" exact="Simvastatin" post="40Â mg od for 14Â days, simvastatin 80Â mg"/>
 <result pre="transplant Miscellaneous Statins Simvastatin 40Â mg od for 14Â days," exact="simvastatin" post="80Â mg od, atorvastatin 40Â mg od PO Anti-inflammatory"/>
 <result pre="40Â mg od for 14Â days, simvastatin 80Â mg od," exact="atorvastatin" post="40Â mg od PO Anti-inflammatory and immunomodulatory effects Hepatotoxicity,"/>
 <result pre="in COVID-19 patients with severe rhabdomyolysis ACEi/ARB Various dosing regimens:" exact="telmisartan" post="80Â mg bid, telmisartan 40Â mg bid, ramipril 2.5Â"/>
 <result pre="severe rhabdomyolysis ACEi/ARB Various dosing regimens: telmisartan 80Â mg bid," exact="telmisartan" post="40Â mg bid, ramipril 2.5Â mg od for 14Â"/>
 <result pre="dosing regimens: telmisartan 80Â mg bid, telmisartan 40Â mg bid," exact="ramipril" post="2.5Â mg od for 14Â days, losartan 100Â mg"/>
 <result pre="2.5Â mg od for 14Â days, losartan 100Â mg od," exact="valsartan" post="80 or 160Â mg for 14Â days (max: 160Â"/>
 <result pre="or 160Â mg for 14Â days (max: 160Â mg bid)," exact="captopril" post="25Â mg, losartan 25Â mg od, losartan 50Â mg"/>
 <result pre="indication for ACEi/ARB; abrupt withdrawal may lead to clinical instability" exact="Azithromycin" post="500Â mg on day 1, then 250Â mg od"/>
 <result pre="on days 2â€&quot;5 in conjunction with a 10-day regimen of" exact="hydroxychloroquine" post="PO Anti-inflammatory and immunomodulatory effects QTc prolongation and ventricular"/>
 <result pre="and ventricular arrhythmias, diarrhea, nausea, abdominal pain, vomiting Hypersensitivity to" exact="azithromycin" post="or other macrolides, history of cholestatic jaundice/hepatic dysfunction associated"/>
 <result pre="other macrolides, history of cholestatic jaundice/hepatic dysfunction associated with prior" exact="azithromycin" post="use InhibitsÂ P-gp/ABCB1 Elderly patients may be more susceptible"/>
 <result pre="be more susceptible to development of Torsades de pointes arrhythmias" exact="Hydroxychloroquine" post="400Â mg bid on day 1, then 200Â mg"/>
 <result pre="component of the formulation CYP2D6, CYP2C8, CYP3A4, CYP3A5 Coadministration of" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate and remdesivir may result in"/>
 <result pre="formulation CYP2D6, CYP2C8, CYP3A4, CYP3A5 Coadministration of chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate and remdesivir may result in reduced antiviral activity"/>
 <result pre="with renal or hepatic function ACEi angiotensin-converting enzyme inhibitors, ALT" exact="alanine" post="aminotransferase, ARB angiotensin II receptor blockers, AST aminotransferase, bid"/>
 <result pre="for the treatment of COVID-19. Recent studies have demonstrated that" exact="hydroxychloroquine" post="and chloroquine may not be effective in treating COVID-19,"/>
 <result pre="treatment of COVID-19. Recent studies have demonstrated that hydroxychloroquine and" exact="chloroquine" post="may not be effective in treating COVID-19, and the"/>
 <result pre="do not outweigh their known and potential risks. However, low-dose" exact="dexamethasone" post="(6Â mg once daily, orally or intravenously, for 10Â"/>
 <result pre="anti-inflammatory and immunosuppressive activity of ruxolitinibFront Oncol20199118610.3389/fonc.2019.0118631788449 35.GaspariVZengariniCGrecoSVangeliVMastroianniASide effects of" exact="ruxolitinib" post="in patients with SARS-CoV-2 infection: two case reportsInt J"/>
 <result pre="Rev202019710255410.1016/j.autrev.2020.10255432380316 69.SooYOChengYWongRet al.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect200410767667810.1111/j.1469-0691.2004.00956.x15214887 70.ArabiYBalkhyHHajeerAHet al.Feasibility, safety,"/>
 <result pre="asked questions and answers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html. Accessed 7 Apr 2020. 97.Low-cost" exact="dexamethasone" post="reduces death by up to one third in hospitalised"/>
 <result pre="2020;15(4):e0231911]PLoS ONE2020152e022839110.1371/journal.pone.022839132084142 106.HungIFLungKCTsoEYet al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="meta-analysis of randomized controlled trialsMicrobiol Immunol20196334334910.1111/1348-0421.12726)31283028 129.KawamuraKIchikadoKTakakiMet al.Adjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
 <result pre="symptoms reliefExpert Rev Respir Med202014553354110.1080/17476348.2020.173018032053044 134.SchoglerAKopfBSEdwardsMRet al.Novel antiviral properties of" exact="azithromycin" post="in cystic fibrosis airway epithelial cellsEur Respir J20154542843910.1183/09031936.0010201425359346 135.LeeNWongCKChanMCWet"/>
 <result pre="J Med2012366201881189010.1056/NEJMoa100383322591294 137.DevauxCARolainJMColsonPet al.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="(SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732613227 139.SahraeiZShabaniMShokouhiSet al.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt J Antimicrob Agents202055410594510.1016/j.ijantimicag.2020.10594532194152 140.ZhouDDaiSMTongQCOVID-19: a recommendation to"/>
 <result pre="Antimicrob Agents202055410594510.1016/j.ijantimicag.2020.10594532194152 140.ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother20207571667167010.1093/jac/dkaa11432196083 141.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from"/>
 <result pre="coronavirus disease 19 (COVID-19)Mayo Clin Proc202010.1016/j.mayocp.2020.03.02432359771 145.GelerisJSunYPlattJet al.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with covid-19N Engl J Med2020382252411241810.1056/NEJMoa201241032379955 146.BoulwareDRPullenMFBangdiwalaASet"/>
 <result pre="with covid-19N Engl J Med2020382252411241810.1056/NEJMoa201241032379955 146.BoulwareDRPullenMFBangdiwalaASet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for covid-19N Engl J Med.202010.1056/NEJMoa201663832492293 147.Letter"/>
 <result pre="prophylaxis for covid-19N Engl J Med.202010.1056/NEJMoa201663832492293 147.Letter revoking EUA for" exact="chloroquine" post="phosphate and hydroxychloroquine sulfate. 2020. https://www.fda.gov/media/138945/download. Accessed 20 Jun"/>
 <result pre="Engl J Med.202010.1056/NEJMoa201663832492293 147.Letter revoking EUA for chloroquine phosphate and" exact="hydroxychloroquine" post="sulfate. 2020. https://www.fda.gov/media/138945/download. Accessed 20 Jun 2020. 148.Low-cost dexamethasone"/>
 <result pre="and hydroxychloroquine sulfate. 2020. https://www.fda.gov/media/138945/download. Accessed 20 Jun 2020. 148.Low-cost" exact="dexamethasone" post="reduces death by up to one third in hospitalised"/>
 <result pre="Jun 2020. 150.BorbaMGSValFFASampaioVSet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
 <result pre="an anti-inflammatory and cardioprotective agentExpert Opin Drug Metab Toxicol201511111781179410.1517/17425255.2015.107639126239119 153.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous" exact="hydroxychloroquine" post="or colchicine therapy does not prevent infection with SARS-CoV-2:"/>
</results>
